The health of their population has always been a great concern for governments of Post-War Europe. In order to achieve their goals they had to work closely together with the pharmaceutical Industry. With the phenomenon of the aging population the importance of development of new drugs is increasing. The increasingly old population of Europe creates a big market for pharmaceutical companies. The pharmaceutical Industry is a very complex sector with close links to other Industries. The chemical Industry for example is an important supplier for materials needed in the process of creating new drugs. Furthermore is the market for pharmaceuticals characterized by extremely little concentration and a huge variety of products. Globally in 1998, the 300 best-selling products held a share of less than 45% of the worlds market. The top two products held 1.3% of the market each.1 This fact creates a necessity for the companies to research new, so called “Blockbuster drugs” to succeed on this market with a high competition. The data on the various methods of drug discovery is enormous and sophisticated. In this paper the structure of the Research & Development sector of the European pharmaceutical industry will be examined, which is of increasing importance for the success of the individual companies. The specific data on the R & D section will be given a general character. Furthermore it will give a brief overview of the different regions in Europe and their individual differences. In the end, the difficulties and challenges of R & D in the pharmaceutical industry will be described and compared to other pharma markets abroad. [1 Data taken from „Combining discovery with development” by Dr. Peter Eddershaw; World pharmaceutical frontiers 2003/2004 ]
Inhaltsverzeichnis (Table of Contents)
- 1. Introduction
- 2. Structure of the Research & Development of the European Pharma-Industry
- Clinical Trials
- Outsourcing
- Company research
- Contract Research Organisations (CRO)
- 3. Regional R & D in Europe
- Most important and effective regions in Europe
- UK
- Involvement of the EU
- the EU and Clinical Trials
- Central and Eastern Europe
- 4. Subjects of R & D
- Biotechnology
- Issue of patents
- 5. Challenges for R & D of the pharmaceutical Industry of Europe
- Patient recruitment
- Competition from abroad
Zielsetzung und Themenschwerpunkte (Objectives and Key Themes)
This paper examines the structure of the Research & Development (R&D) sector within the European pharmaceutical industry, highlighting its importance for individual company success. It provides a general overview of R&D, focusing on different European regions and their unique characteristics. Finally, it addresses the challenges and difficulties faced by the European pharmaceutical industry's R&D sector in comparison to other global markets.
- Structure of European pharmaceutical R&D
- Regional variations in European pharmaceutical R&D
- R&D expenditure and employment trends in Europe
- Key subjects of R&D within the European pharmaceutical industry
- Challenges faced by European pharmaceutical R&D
Zusammenfassung der Kapitel (Chapter Summaries)
1. Introduction: This introductory chapter establishes the context of the European pharmaceutical industry, emphasizing the growing importance of drug development due to an aging population and the industry's complex interplay with other sectors like the chemical industry. It highlights the highly competitive market characterized by a vast array of products and the necessity for companies to develop blockbuster drugs. The chapter lays the groundwork for the subsequent analysis of the European pharmaceutical industry's R&D structure, regional variations, and the challenges it faces.
2. Structure of the Research and Development of the European Pharma-Industry: This chapter delves into the structure of the European pharmaceutical industry's R&D sector, demonstrating its growth despite economic slowdowns. Using data on R&D employment and expenditure, it illustrates the industry's continued investment in innovation. The chapter further analyzes the competitive landscape, showing that while European companies were once leaders, they've faced increased global competition in recent decades. Key aspects of the R&D structure, including clinical trials and outsourcing, are briefly introduced, setting the stage for a more detailed examination in later sections (which are not included in this preview).
3. Regional R & D in Europe: This chapter focuses on the geographical distribution of R&D activity within Europe. It would discuss the varying levels of R&D investment and success across different European regions, likely highlighting key players like the UK and contrasting them with other areas. The role of the EU in fostering and regulating R&D would also be a major focus. The chapter would likely provide a nuanced understanding of how regional factors influence the overall performance of the European pharmaceutical R&D sector.
4. Subjects of R & D: This chapter discusses the specific areas of research and development undertaken by the European pharmaceutical industry. A key focus would likely be on biotechnology and its associated challenges, particularly concerning patents and intellectual property rights. It would illustrate how emerging fields like biotechnology contribute to innovation within the industry.
5. Challenges for R & D of the pharmaceutical Industry of Europe: This chapter analyzes the challenges confronting the R&D sector in the European pharmaceutical industry. Two key challenges are identified: patient recruitment for clinical trials and increasing competition from pharmaceutical companies outside of Europe. This section would likely present a comparative analysis, highlighting how these challenges impact the competitiveness of European companies on the global stage.
Schlüsselwörter (Keywords)
European pharmaceutical industry, Research & Development (R&D), Clinical trials, Outsourcing, Biotechnology, Patents, Competition, Regional variations, Aging population, Blockbuster drugs, EU regulations.
European Pharmaceutical Industry R&D: FAQ
What is the purpose of this document?
This document provides a comprehensive preview of a paper examining the structure and challenges of the Research & Development (R&D) sector within the European pharmaceutical industry. It includes a table of contents, objectives and key themes, chapter summaries, and keywords.
What are the key themes explored in the paper?
The paper explores the structure of European pharmaceutical R&D, regional variations in R&D activity, R&D expenditure and employment trends, key subjects of R&D (such as biotechnology and patents), and the challenges faced by European pharmaceutical R&D, including patient recruitment and global competition.
What is the structure of the European pharmaceutical R&D sector, according to the preview?
The preview indicates that the R&D sector is complex, involving clinical trials, outsourcing to Contract Research Organisations (CROs), and significant company-based research. It highlights continued investment in innovation despite economic challenges and increased global competition.
How does the paper address regional variations in European pharmaceutical R&D?
The paper analyzes the geographical distribution of R&D activity across Europe, comparing the performance of different regions, highlighting key players (like the UK), and examining the role of the EU in fostering and regulating R&D.
What are some key subjects of R&D in the European pharmaceutical industry?
The preview mentions biotechnology as a key area of research and development, along with the associated challenges of patents and intellectual property rights.
What are the main challenges facing European pharmaceutical R&D?
The preview identifies two major challenges: difficulties in patient recruitment for clinical trials and increased competition from pharmaceutical companies based outside of Europe.
What specific aspects of the R&D structure are discussed?
The preview mentions clinical trials and outsourcing as key aspects of the R&D structure, indicating a more detailed examination of these topics within the full paper (though details are not provided in this preview).
What is the significance of the aging population in the context of the European pharmaceutical industry?
The preview suggests that an aging population contributes to the growing importance of drug development and the increased need for innovation in the pharmaceutical industry.
What is the role of the EU in the context of European pharmaceutical R&D?
The preview indicates that the EU plays a significant role in fostering and regulating R&D within the European pharmaceutical industry. Further details are promised in the full paper.
What are the keywords associated with this research?
Keywords include: European pharmaceutical industry, Research & Development (R&D), Clinical trials, Outsourcing, Biotechnology, Patents, Competition, Regional variations, Aging population, Blockbuster drugs, and EU regulations.
- Quote paper
- Arne Noack (Author), 2003, Research & Development of the european pharmaceutical industry, Munich, GRIN Verlag, https://www.hausarbeiten.de/document/22850
